Viewing Study NCT04217135

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 10:37 PM
Ignite Modification Date: 2026-01-31 @ 7:57 AM
Study NCT ID: NCT04217135
Status: UNKNOWN
Last Update Posted: 2022-01-06
First Post: 2019-12-29
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation
Sponsor: Kaohsiung Veterans General Hospital.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Systolic Heart Failure Stage D (Disorder) View
None Mitral Regurgitation View
Keywords:

Keywords

Keyword Brief Keyword Text View
None high-dose hydralazine View
None mitral regurgitation View
None severe systolic heart failure View
None heart failure rehospitalization View
None all-cause mortality View